Details of the Drug Combinations

General Information of This Drug (ID: DMXZRW0)

• Drug Name: DTI-015 (DMXZRW0)
• Synonyms: Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics

Indication

Brain cancer; ICD 11: 2A00; Status: Approved [1]; Glioblastoma of brain; ICD 11: 2A00.00; Status: Approved [2]; Liver cancer; ICD 11: 2C12; Status: Approved [3]; Malignant glioma; ICD 11: 2A00.0; Status: Approved [4]; Plasma cell myeloma; ICD 11: 2A83.1; Status: Approved [5]; Classic Hodgkin lymphoma; ICD 11: N.A.; Status: Investigative [5]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
DTI-015 + Idarubicin	DC41X9E	Idarubicin	Glioblastoma? (Cell Line: T98G)	[6]

7 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dapagliflozin + DTI-015	DCSIKV8	Dapagliflozin	Pediatric Brain Tumor	[7]
Irinotecan + DTI-015	DCTTN11	Irinotecan	Brain and Central Nervous System Tumors	[8]
Lomustine + DTI-015	DCA70XC	Lomustine	Brain and Central Nervous System Tumors	[9]
Lomustine + DTI-015	DCV5KDL	Lomustine	Glioblastoma Multiforme	[10]
Temozolomide + DTI-015	DC9T61Y	Temozolomide	Brain and Central Nervous System Tumors	[9]
Thiotepa + DTI-015	DCJTCOB	Thiotepa	Central Nervous System Lymphoma	[11]
Etoposide + DTI-015	DC0MIZ8	Etoposide	Lymphoma	[12]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6800).
• [2] Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol). Neuro Oncol. 2007 Jan;9(1):12-9.
• [3] Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.
• [4] Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia. 2003 Jan-Feb;5(1):9-16.
• [5] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [6] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [7] ClinicalTrials.gov (NCT05521984) Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
• [8] ClinicalTrials.gov (NCT00027612) Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
• [9] ClinicalTrials.gov (NCT00004259) Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
• [10] ClinicalTrials.gov (NCT03382977) Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT01011920) Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
• [12] ClinicalTrials.gov (NCT00345865) Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma